nach oben

Drugs

Erschienen in:

01.04.2005 | Adis Drug Profile

Mycophenolate Sodium Delayed Release

Prevention of Renal Transplant Rejection

verfasst von: Monique P. Curran, Gillian M. Keating

Erschienen in: Drugs | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

▲ Mycophenolate sodium delayed release is an enteric-coated formulation designed to release the active agent (mycophenolic acid) in the small intestine.
▲ Mycophenolate sodium delayed release was equivalent in efficacy to, and had a similar tolerability profile as, mycophenolate mofetil in de novo renal transplant patients treated with ciclosporin (cyclosporin) and corticosteroids in a well designed study of 12 month’s duration.
▲ Maintenance renal transplant patients treated with ciclosporin and corticosteroids were converted from mycophenolate mofetil to mycophenolate sodium delayed release without any alteration in efficacy or tolerability in a well designed study of 12 month’s duration.
▲ The incidence of gastrointestinal adverse events with mycophenolate sodium delayed release was similar to that with mycophenolate mofetil.

The use of trade names is for product identification purposes only and does not imply endorsement.

Bardsley-Elliot A, Noble S, Foster RH. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation. Biodrugs 1999 Nov; 12: 363–410PubMedCrossRef

Novartis. Myfortic® (mycophenolic acid*) delayed release* as mycophenolate sodium. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2004

Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004 Jun; 5(6): 1333–45PubMedCrossRef

Budde K, Glander P, Hahn U, et al. Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance renal transplant patients [abstract no. 1036]. Am J Transplant 2002; 2 Suppl. 3: 399

Schuurman HJ, Pally C, Fringeli-Tanner M, et al. Comparative efficacy of mycophenolate sodium (MPS) and mycophenolate mofetil (MMF) with and without cyclosporine in rat transplantation models. Transplantation 2001 Dec 15; 72: 1776–83PubMedCrossRef

Cozzi E, Vial C, Ostlie D, et al. Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. Xenotransplantation 2003; 10(4): 300–10PubMedCrossRef

Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001; 33: 3241–4PubMedCrossRef

Schmouder R, Arns W, Merkel F, et al. Pharmacokinetics of ERL080A: a new enteric coated formulation of mycophenolic acid-sodium. Transplantation 1999 Apr 15; 67: S203CrossRef

Ettenger R, Choi L, Al-Akash S, et al. Myfortic™ delivers therapeutic mycophenolic acid exposure in pediatric renal transplant patients [abstract no. 216]. Am J Transplant 2002; 2 Suppl. 3: 193CrossRef

10.

Kaplan B, Bastien MC, Herwig-Ulf MK, et al. Steady-state pharmacokinetics of enteric-coated mycophenolate sodium (Myfortic®) in stable renal transplant patients differ during concomitant treatment with Neoral® or tacrolimus. Am J Transplant 2004 May; 4 Suppl. 8: 230

11.

Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004 Feb; 4(2): 231–6PubMedCrossRef

12.

Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2003 Feb; 4(2): 237–43CrossRef

13.

David-Neto E, Turconi A, Giron F, et al. A study about the safety and tolerability of the conversion to enteric-coated mycophenolate sodium from mycophenolate mofetil in stable pediatric renal transplant recipients. Am J Transplant 2004 May; 4 Suppl. 8: 575

14.

Novartis Pharmaceuticals UK Ltd. Myfortic film-coated gastroresistant tablets. Surrey, UK: Novartis Pharmaceuticals UK Ltd, 2004

15.

Novartis. FDA approves Myfortic® to prevent organ rejection after kidney transplantation [media release]. 2004

16.

Novartis Pharma AG. Novartis successfully completes European Mutual Recognition Procedure for Myfortic® — its new immunosuppressant [media release]. 2004

17.

Nashan B, Ivens K, Suwelack B, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic PROspective Multicenter Study. Transplant Proc 2004 Mar; 36 Suppl. 2: 521–3CrossRef

18.

Novartis AG, Data on file, 2005

Titel: Mycophenolate Sodium Delayed Release
Prevention of Renal Transplant Rejection
verfasst von: Monique P. Curran
Gillian M. Keating
Publikationsdatum: 01.04.2005
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 6/2005
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200565060-00007

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Mycophenolate Sodium Delayed Release

Prevention of Renal Transplant Rejection

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2005

Mycophenolate Sodium Delayed Release

Mycophenolate Sodium Delayed Release

Tacrolimus Ointment

Optimising the Use of β-Adrenoceptor Antagonists in Coronary Artery Disease

Peginterferon-α-2a (40kD)

Anaesthetic Agents for Advanced Regional Anaesthesia